<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05114785</url>
  </required_header>
  <id_info>
    <org_study_id>IRAS 301141</org_study_id>
    <nct_id>NCT05114785</nct_id>
  </id_info>
  <brief_title>Heart Failure With Preserved Ejection Fraction: Evaluation and Recognition by CMR</brief_title>
  <acronym>PREFER-CMR</acronym>
  <official_title>PReserved Ejection Fraction Evaluation and Recognition by Cardiac Magnetic Resonance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of East Anglia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinical Research and Trials Unit (Norfolk &amp; Norwich University Hospital, UK)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of East Anglia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart failure with preserved ejection fraction (HFpEF) is a common and growing condition with&#xD;
      a poor prognosis but the pathophysiology and management are still being investigated. The&#xD;
      PREFER-CMR project aims to evaluate and validate the application of novel 4D cardiac magnetic&#xD;
      resonance flow dynamic methods to measure left ventricular pressures and validate these&#xD;
      measurements with direct pressure measurement by coronary angiography. This is a prospective&#xD;
      observational study of patients with HFpEF undergoing clinical evaluation with coronary&#xD;
      angiography who will also undergo contemporaneous cardiac MRI. The primary outcome will be&#xD;
      the level of agreement between the two methods using angiography as the reference method.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart failure with preserved ejection fraction (HFpEF) is prevalent, increasing in incidence&#xD;
      and has a poor prognosis. Accurate left ventricular (LV) haemodynamic assessment is needed to&#xD;
      diagnose and manage patients with HFpEF. The reference method for assessment is an invasive&#xD;
      study using catheters to measure intra-ventricular pressure but this is rarely done due to&#xD;
      its invasive nature, high procedural costs and lack of expertise, despite the fact that&#xD;
      haemodynamic guided therapy is associated with reduced re-hospitalisation and mortality.&#xD;
      Non-invasive methods of LV haemodynamic assessment are inaccurate. The Investigators have&#xD;
      developed an accurate four-dimensional flow cardiac magnetic resonance (4D flow CMR) protocol&#xD;
      which is non-invasive and addresses the issues with existing practices to evaluate HFpEF.&#xD;
      This observational-analytical study aims to assess the utility of a non-invasive 4D flow CMR&#xD;
      protocol for haemodynamic assessment of HFpEF, to generate clinical data to support future&#xD;
      clinical trials, clinical translation and patient benefit. This research study will involve&#xD;
      generating a precise haemodynamic model using invasive and non-invasive data of prospectively&#xD;
      recruited patients. This model will be also optimised in clinical patients with arrhythmias.&#xD;
      Also, observational data will be collected to test the model's prognostic value.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">January 2032</completion_date>
  <primary_completion_date type="Anticipated">January 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular pressure measured by cardiac magnetic resonance imaging and invasive angiography</measure>
    <time_frame>30 days</time_frame>
    <description>Agreement of non-invasively modelled left ventricular pressure by cardiac magnetic resonance imaging compared to left ventricular pressure measured by invasive angiography.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prognostic relevance of left ventricular pressures measured by cardiac MRI</measure>
    <time_frame>Ten years</time_frame>
    <description>Are cardiac MRI modelled left ventricular pressures associated with MACE events including re-hospitalisation, stroke, myocardial infarction and death</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Heart Failure With Preserved Ejection Fraction</condition>
  <condition>Heart Diseases</condition>
  <arm_group>
    <arm_group_label>HFpEF group</arm_group_label>
    <description>Suspected HFpEF group: 80 patients will be recruited with history of dyspnoea, LV ejection fraction ≥ 50%, raised NTproBNP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>20 patients with suspected CAD but with no dyspnoea and normal echocardiogram.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Multi Parametric Cardiac Magnetic Resonance</intervention_name>
    <description>Research based Cardiac MRI evaluation to determine cardiovascular haemodynamics</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>HFpEF group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        -  Suspected heart failure patients&#xD;
&#xD;
          -  Suspected coronary artery disease patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults: age≥18 years.&#xD;
&#xD;
          2. Typical HF symptoms (NYHA stage&gt;I) within the last six months.&#xD;
&#xD;
          3. Raised NTproBNP (&gt;400 pg/ml)&#xD;
&#xD;
          4. EF&gt;50 % with the absence of structural heart disease on TTE (except left ventricular&#xD;
             hypertrophy or left atrial enlargement).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients unable/unwilling to provide informed consent.&#xD;
&#xD;
          2. Bodyweight&gt;120 kg or inability to lie flat/still.&#xD;
&#xD;
          3. Contraindication for invasive workup (allergy to contrast, severe renal insufficiency&#xD;
             with estimated glomerular filtration rate (eGRF)&lt;30 ml/min).&#xD;
&#xD;
          4. Contraindications for a contrast-enhanced CMR study (allergy to contrast, incompatible&#xD;
             devices or implants, severe claustrophobia).&#xD;
&#xD;
          5. Previous medical history of EF &lt;50%&#xD;
&#xD;
          6. Pregnancy&#xD;
&#xD;
        The extended observational arm of the study will have wider eligibility criteria&#xD;
&#xD;
        - Patients undergoing cardiac MRI for clinical indications irrespective of EF&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pankaj Garg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of East Anglia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pankaj Garg, MD</last_name>
    <phone>+441603591721</phone>
    <email>p.garg@uea.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marcus D Flather, MBBS</last_name>
    <email>m.flather@uea.ac.uk</email>
  </overall_contact_backup>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 28, 2021</study_first_submitted>
  <study_first_submitted_qc>November 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>hemodynamics</keyword>
  <keyword>magnetic resonance imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The dataset of this study are available at the discretion of the Principal Investigator on reasonable request.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

